S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%
Next Bullish Trade
Sign in
MRK

MRK

+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · MRK

Momentum reads · latest daily bar
Last
$127.50
-0.13 (-0.10%)
Mkt cap
$314.9B
Healthcare
RSI(14)
57.9
neutral
Stochastic %K
57.1
neutral
MFI(14)
46.5
neutral
ADX(14)
17.2
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $16.3B $-4.2B $-3.2B $2.9B -26.0% -19.7%
2025-12-31 $16.4B $3.0B $4.1B $1.8B 18.1% 24.8%
2025-09-30 $17.3B $5.8B $6.6B $6.8B 33.5% 37.9%
2025-06-30 $15.8B $4.4B $5.6B $2.5B 28.0% 35.1%
2025-03-31 $15.5B $5.1B $5.9B $1.2B 32.7% 38.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare MRK vs peers

Line MRK up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing MRK no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + ABBV + PFE + TMO
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with MRK

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.4 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK ★ $315B 35.9 13.2 4.8 12.2 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.1 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.7 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.3 19.5 4.4 21.4 3.8 40.9% 6.2% 11.3% 2.79%
ABT $175B 28.2 16.6 3.9 15.6 3.4 56.5% 7.8% -19.7% 3.62%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 36.92%

HolderShares% out
Blackrock Inc. 225,830,330 9.14%
Vanguard Capital Management LLC 160,987,624 6.52%
State Street Corporation 119,325,673 4.83%
Wellington Management Group, LLP 84,314,971 3.41%
Vanguard Portfolio Management LLC 67,304,305 2.73%
Geode Capital Management, LLC 59,558,154 2.41%
JPMORGAN CHASE & CO 52,972,983 2.14%
Charles Schwab Investment Management 49,765,225 2.01%
Morgan Stanley 47,632,487 1.93%
FMR, LLC 44,516,010 1.80%

Insider activity · 90d

15 buys / 0 sells · ratio 15.0 · Finnhub

  • Seidman Christine E BUY 21,291 @ $128.50
  • Karsanbhai Surendralal Lanca BUY 5,519 @ $128.50
  • Coe Mary Ellen BUY 31,999 @ $128.50
  • Mayo Stephen BUY 14,825 @ $118.72
  • Seidman Christine E BUY 21,228 @ $118.72
  • Karsanbhai Surendralal Lanca BUY 5,392 @ $118.72
  • Coe Mary Ellen BUY 31,766 @ $118.72
  • Rothman Paul BUY 34,945 @ $118.72
  • Warden Kathy J BUY 17,890 @ $118.72
  • THULIN INGE G BUY 27,470 @ $118.72

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$100.0
Mean
$132.77779
High
$155.0
Analysts
27
Recommendation distribution · period 2026-07-01
9
16
11
Revision trend (2026-04-01 → 2026-07-01): net 24 → 25 +1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-01 PRIMARY DOCUMENT view ·
4 2026-07-01 PRIMARY DOCUMENT view ·
4 2026-07-01 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
8-K 2026-05-28 FORM 8-K view ·
8-K 2026-05-22 8-K view ·
13F-HR 2026-05-13 Institutional holdings (13F) view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-05 PRIMARY DOCUMENT view ·
4 2026-05-05 PRIMARY DOCUMENT view ·
10-Q 2026-05-04 1Q26 FORM 10-Q view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
8-K 2026-04-30 FORM 8-K view ·
DEF 14A 2026-04-08 DEF 14A view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
10-K 2026-02-24 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 view ·
13F-HR 2026-02-17 Institutional holdings (13F) view ·
4 2026-02-12 PRIMARY DOCUMENT view ·
4 2026-02-10 PRIMARY DOCUMENT view ·
4 2026-02-09 PRIMARY DOCUMENT view ·
4 2026-02-09 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, a…

Options picks · MRK

ITM + OTM ideas from the latest scan

Loading…

Congress trades · MRK

STOCK Act disclosures

Loading…

SEC filings & insiders · MRK

EDGAR · live

Loading…

Holders · MRK

Institutions & insider activity

Loading…